Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a five-day ointment improve sun-damaged skin? new study investigates

NCT ID NCT07657988

Disease control Sponsor: Avant Health LLC Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows adults with actinic keratosis (precancerous sun-damaged spots) on the face who are already using tirbanibulin ointment as part of their regular care. Researchers want to see if the treatment improves overall skin appearance and texture over 57 days. Participants answer online surveys at the start and end of the study.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
tirbanibulin ointment (Klisyri)
What this could lead to
If effective, tirbanibulin could offer a convenient, short-course treatment to improve skin appearance and texture in people with actinic keratosis.
What could go wrong
This is a small, observational pilot study with only 30 participants and no comparison group, so results may not apply to everyone. The treatment may not work as well in real-world settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2026

Expected to finish

Oct 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Study-eligible AK patients receiving usual care treatment in routine clinical practices in the U.S.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosed with AK on the face. * Has clinically typical, visible, and discrete 4-12 AK lesions on the face. * Considered as a potential candidate for tirbanibulin (Klisyri®) treatment to manage their AK lesions on the face. * Male or female, aged 18 years and above at the time of initiation of treatment with tirbanibulin. * Willing to avoid excessive sun or UV exposure, and/or use relevant sunscreen protection and protective clothing during the study duration. * Able to read and write in English. * Provide consent to participate in the study. * Willing to comply with all study procedures (including photography tasks) and be available for the duration of the study. Exclusion Criteria: * Patients with any dermatological condition of the face that could interfere with clinical evaluations. * Hypertrophic AK lesions, open wounds, or suspected skin cancers within proximity of the treatment area. * Anticipated need for in-patient hospitalization or in-patient surgery within the next 2 months. * Patients unable to comply with the requirements of the study or patients who, in the opinion of the study physician should not participate in the study. * Patients for whom medical chart is inaccessible to physicians to complete baseline data collection.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Actinic keratosis (AK) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

actinic keratosis Personal Satisfaction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Actinic keratosis (AK)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    2 sites. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Ablon Skin Institute and Research Center

    RECRUITING

    Manhattan Beach, California, 90266, United States

  • Dermatology & Laser Center of Charleston

    RECRUITING

    Charleston, South Carolina, 29414, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.